Search
Higenamine
go.drugbank.com/drugs/DB12779InvestigationalHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
Categories: Compounds used in a research, industrial, or household settingBrentuximab
go.drugbank.com/drugs/DB05471InvestigationalSGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared
Minaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. … Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Synonyms: N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamineCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalIt shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community. … Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnLike many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient. … Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia.
Alglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.
CHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.